Galaxy Biomedical Investment Co., Ltd. reported earnings results for the nine months ended September 30, 2021. For the nine months, the company reported sales was CNY 789.8 million compared to CNY 802.23 million a year ago. Revenue was CNY 789.8 million compared to CNY 802.23 million a year ago. Net loss was CNY 157.7 million compared to net income of CNY 35.3 million a year ago. Basic loss per share from continuing operations was CNY 0.1434 compared to basic earnings per share from continuing operations of CNY 0.0321 a year ago. Diluted loss per share from continuing operations was CNY 0.1434 compared to diluted earnings per share from continuing operations of CNY 0.0321 a year ago.